Skip to main content

Therapeutic Proteins and Oral Vaccines Market Growth Opportunities, Driving Factors by Manufacturers, Regions, Type and Application, Forecast Analysis to 2028

 


The global therapeutic proteins and oral vaccines market size is estimated to be valued at US$ 201,042.7 million in 2020 and is expected to exhibit a CAGR of 6.7% over the forecast period (2020-2027).

The increasing investments by key players for the development of promising therapies for treatment of different disease conditions is expected to drive the market growth over the forecast period. For instance, in March 2020, research scientists at Migal Galilee Research Institute Ltd, the research and development center of MigVax Ltd, announced to develop a oral vaccine for a deadly coronavirus virus affecting poultry could be adapted for human use against the novel coronavirus known as 2019-nCoV and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Moreover, increasing prevalence of oncology disease is expected to drive growth of the global therapeutic proteins and oral vaccines market. For instance, according to the World Health Organization report published in September 2018, cancer is the second leading cause of death globally, with around 70% of deaths occurring in low and middle income countries.

Global Therapeutic Proteins and Oral Vaccines Market- Impact of Coronavirus (Covid-19) Pandemic

The increasing prevalence of COVID-19 has caused production factories to shutdown in almost all sectors, and also affected the supply of raw materials and Active Pharmaceutical Ingredients (API) of the manufacturing companies across the globe. Moreover, various guidelines have been implemented by regulatory authorities for manufacturing of active pharmaceutical ingredients and pharmaceutical products to avoid the spread of COVID-19 and also to reduce the contamination of active pharmaceutical ingredients during the manufacturing process of pharmaceuticals products such as vaccines, tablets, and others.

According to the U.S. Food Drug and Administration’s report of June 2020, owing to the COVID-19 public health emergency, drug manufacturers are required to abide by the following current good manufacturing practice (CGMP) regulations and recommendations regarding restriction of sick employees from production areas. 1) Any employee or worker in a production unit should be medically evaluated for infectious diseases such as COVID-19. 2) If any of individual is exhibiting COVID-19 symptoms, they shall be restricted from entering the production house premises of the company to prevent contamination of drugs and active pharmaceutical ingredients (API).

Thus, the COVID-19 pandemic has negatively affected the Global therapeutic protein and oral vaccine market.

 

Comments

Popular posts from this blog

The Global Autoclave Equipment Market Continues To Grow Owing To the Rising Demand from Healthcare Sectors for Sterilizing Medical Equipment to Ensure the Safety of the Post-Surgical Period

  Autoclave equipment is the most popular sterilization method in the industry and is used for many applications including the manufacture of food products. It is widely used in the foodservice industry to sterilize and cleanse equipment used in the process of preparing and serving food. The autoclave is the abbreviated form of autolysis which means oxidation. Autoclaves have various parts including an electric motor, a condenser, and a burner. Autoclave equipment includes vials for sealing the autoclave, a glass or plastic container that has been lined with wax or plastic, and the appropriate autoclave equipment accessories such thermometer for measuring the temperature of the autoclave. All modern steam sterilizing equipment & autoclave machines provide a much-refined workflow experience, which makes you reconsider whether or not steam sterilizing is all it can be. A wide range of sterilization methods is used for sterilizing your medical and laboratory specimen so the right ...

Biologics Market Increasing Prevalence of Chronic Diseases to Augment Growth of the market

  A  biologic  drug ( biologics ) is a product that is produced from living organisms or contains components of living organisms.  Biologic  drugs are widely used to prevent, diagnose, treat, or cure a variety of diseases, including infectious diseases, autoimmune disorders, chronic kidney disease, and cancer. Market Dynamics In the recent past, several novel biopharmaceutical products were approved by major regulatory bodies and major players in the market have launched various novel and innovative biopharmaceutical products. Rapid approvals and launches of novel products in the market are expected to be major drivers for growth of the biologicsmarket . 

Treprostinil Drugs Market - High Prevalence of Pulmonary Arterial Hypertension and R&D of New Formulations of Treprostinil to Augment Growth of market

  Treprostinil is an antihypertensive agent used to treat patients with pulmonary arterial hypertension. It can also be used in the treatment of Degos disease, an extremely rare disorder in which small and medium sized arteries become blocked (occlusive arteriopathy), restricting the flow of blood to affected areas. Market Dynamics High prevalence of pulmonary arterial hypertension is expected to propel growth of the treprostinil drugs market . For instance, according to the study, ‘High Geographic Prevalence of Pulmonary Artery Hypertension: Associations with Ethnicity, Drug Use, and Altitude’, published in February 2020, in the journal Pulmonary Circulation, the overall pulmonary arterial hypertension incidence was 14 cases per million and the annual period prevalence of pulmonary arterial hypertension was 93 cases per million. Decline in new prescriptions for treprostinil-based products is expected to hinder growth of the treprostinil drugs market. For instance, United The...